18889881171
Kalkine 0
countryflagUS
Logi

AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%
AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%

Humacyte Inc

Healthcare US HUMA

1.375USD
-0.075(5.17%)

Last update at 2025-04-04T18:50:00Z

Day Range

1.301.42
LowHigh

52 Week Range

1.967.78
LowHigh

Fundamentals

  • Previous Close 1.45
  • Market Cap891.94M
  • Volume2184630
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-93.56900M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 1.56M
  • Diluted EPS TTM-1.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2019-12-312020-12-312021-12-312022-12-31-60M-50M-40M-30M-20M-10M0M10M20M30M40M50M60M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M50M100M150M200M250M300M350M400M450M
Total Assets
Total Liabilities

Change in Cash

2019-12-312020-12-312021-12-312022-12-31-60M-40M-20M0M20M40M60M80M100M120M140M160M

Total Operating Cash

2019-12-312020-12-312021-12-312022-12-31-82M-80M-78M-76M-74M-72M-70M-68M-66M-64M-62M-60M-58M-56M-54M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -11.96500M -26.47700M -66.52400M -
Minority interest - - - -
Net income 64.22M 37.54M -68.72600M -
Selling general administrative 22.88M 21.13M 12.01M 16.27M
Selling and marketing expenses - - - -
Gross profit - -0.04900M - 6.19M
Reconciled depreciation 8.21M 8.24M 8.35M -
Ebit -84.57800M -81.20800M -64.60000M -85.69100M
Ebitda -160.34500M -136.98000M -55.97100M -81.00200M
Depreciation and amortization -75.76700M -55.77200M 8.63M 4.69M
Non operating income net other 78.81M 59.08M - -
Operating income -84.57800M -81.20800M -64.60000M -85.69100M
Other operating expenses 84.58M 81.21M 64.60M 91.88M
Interest expense 6.20M 4.35M 2.20M 2.30M
Tax provision - - - -
Interest income 2.63M 0.02M 0.28M -
Net interest income -3.57100M -4.33200M -1.92400M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -76.18400M -64.01300M 2.20M -
Total revenue 0.00000M 0.00000M 0.00000M 6.19M
Total operating expenses 84.58M 81.21M 64.60M 91.88M
Cost of revenue - 0.05M - -
Total other income expense net 72.61M 54.73M -1.92400M -
Discontinued operations - - - -
Net income from continuing ops -11.96500M -26.47700M -66.52400M -
Net income applicable to common shares -11.96500M -26.47700M -66.52400M -85.42200M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 128.22M 204.30M 286.53M 106.69M -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.69M 2.33M 3.66M 0.15M -
Total liab 114.68M 87.37M 164.36M 457.00M -
Total stockholder equity 13.55M 116.93M 122.17M -350.31700M -
Deferred long term liab - - - - -
Other current liab 11.95M 9.41M 2.20M 4.74M -
Common stock 0.01000M 543.47M 536.75M 0.00100M 0.02M
Capital stock 0.01000M 0.01000M 0.01000M 0.00100M -
Retained earnings -537.31400M -426.53800M -414.57300M -388.09600M -321.57200M
Other liab - 27.97M 104.84M 0.14M -
Good will - - - - -
Other assets - - - - -
Cash 80.59M 149.77M 217.50M 39.93M -
Cash and equivalents - - - - -
Total current liabilities 18.44M 19.58M 11.05M 11.23M 10.84M
Current deferred revenue -2.61300M - 4.73M - -
Net debt -22.48600M -102.01200M -169.03200M -11.06800M -
Short term debt 2.61M 8.57M 2.03M 4.22M -
Short long term debt - 8.57M - 2.45M -
Short long term debt total 58.11M 47.76M 48.47M 28.86M -
Other stockholder equity 550.85M 543.46M 536.24M 37.78M -
Property plant equipment - 30.04M 35.03M 65.24M 73.74M
Total current assets 83.28M 154.21M 229.34M 41.45M 94.95M
Long term investments - - - 100.02M -
Net tangible assets - 116.93M 122.17M 93.01M -288.78800M
Short term investments 0.00000M 2.11M 8.00M 0.00000M -
Net receivables 0.00000M 0.03M 0.18M 0.11M 0.60M
Long term debt 38.60M 20.34M 27.36M 0.82M -
Inventory - -0.03100M - - -
Accounts payable 6.49M 1.59M 2.09M 2.27M 3.27M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - -822.77300M - -
Additional paid in capital - - - - -
Common stock total equity - 0.01000M 0.01000M 94.16M -
Preferred stock total equity - - - - -
Retained earnings total equity - -426.53800M -414.57300M 1.42M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 20.05M 0.73M 100.02M -
Deferred long term asset charges - - - - -
Non current assets total 44.95M 50.09M 57.19M 65.24M -
Capital lease obligations 18.91M 21.79M 21.11M 25.59M -
Long term debt total - 20.34M 27.36M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 5.89M -8.00000M -0.26800M -8.00000M
Change to liabilities -0.43500M 1.72M -0.88900M 1.84M
Total cashflows from investing activities 4.84M -8.22000M -0.26800M -8.12500M
Net borrowings -1.98100M 29.66M 1.75M -1.29200M
Total cash from financing activities -1.44600M 266.98M 2.05M -0.07400M
Change to operating activities 1.39M -0.29700M -1.96800M 0.64M
Net income -11.96500M -26.47700M -66.52400M -85.42200M
Change in cash -67.73000M 177.57M -53.78400M -79.98600M
Begin period cash flow 217.50M 39.93M 93.71M 173.70M
End period cash flow 149.77M 217.50M 39.93M 93.71M
Total cash from operating activities -71.12900M -81.19000M -55.56800M -71.78700M
Issuance of capital stock - - - -
Depreciation 8.21M 8.24M 8.35M 4.69M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - -0.18100M -2.25700M -
Change to account receivables 0.14M -0.06300M 0.49M -0.18500M
Sale purchase of stock 0.54M 243.00M - -
Other cashflows from financing activities 4.84M 268.71M 3.55M 1.22M
Change to netincome -69.99400M -48.96600M 4.97M 4.59M
Capital expenditures 1.05M 0.22M 0.32M 8.12M
Change receivables 0.14M -0.06300M - -
Cash flows other operating 3.42M -14.56400M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -67.73000M 177.57M - -
Change in working capital 1.03M -0.55700M -2.36900M 2.25M
Stock based compensation 6.18M 10.15M 4.69M 4.46M
Other non cash items -74.41400M -54.74200M 0.10M -83.18200M
Free cash flow -72.17700M -81.41000M -55.88600M -79.91200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
HUMA
Humacyte Inc		 -0.075 5.17% 1.38 - - 153.91 25.41 -3.3301
NVO
Novo Nordisk A/S		 -4.44 6.62% 62.66 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.842 5.72% 63.30 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -5.74 1.19% 478.27 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -27.19 4.45% 583.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Humacyte Inc

2525 East North Carolina Highway 54, Durham, NC, United States, 27713

Key Executives

Name Title Year Born
Dr. Laura E. Niklason M.D., Ph.D. Founder, Pres, CEO & Director 1963
Mr. Dale A. Sander CFO, Chief Corp. Devel. Officer & Treasurer 1960
Dr. Heather Ledbetter Prichard Ph.D. Chief Operating Officer 1978
Dr. Juliana L. Blum Ph.D. Co-Founder & Exec. VP of Corp. Devel. NA
Ms. Sabrina Osborne Exec. VP of Bus. Strategy & People NA
Mr. William John Scheessele Chief Commercial Officer 1972
Dr. Shamik J. Parikh M.D. Chief Medical Officer 1973
Mr. Harold Alterson Sr. VP of Quality NA
Dr. Yang Cao M.D., Ph.D. Chief Regulatory Officer NA
Dr. Laura E. Niklason M.D., Ph.D. Founder, President, CEO & Director 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.